AGT and early-onset autosomal dominant Alzheimer disease: Collectively, these findings highlight the potential involvement of angiotensin II in several pathological pathways in Alzheimer's disease and frame our core hypothesis that pharmacological intervention against angiotensin II signalling by losartan might provide protection against multiple processes that cause the progression of Alzheimer's disease brain pathology.